Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: Putting it together with a translational perspective

Annals of Oncology

Volumn 27, Issue 9, 2016, Pages 1685-1695

  Shenoy, Niraj ^a   Pagliaro, L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clear cell RCC; Epigenetics; HIF pathway; Molecular pathogenesis; Translational research; Von Hippel Lindau

Indexed keywords

BMI1 PROTEIN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TWIST1 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VON HIPPEL LINDAU PROTEIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VHL PROTEIN, HUMAN;

ARTICLE; EPIGENETICS; GENE ACTIVITY; GENE INACTIVATION; GENETIC TRANSCRIPTION; GENOME WIDE EPIGENETIC; GERMLINE MUTATION; HUMAN; IMMUNE EVASION; KIDNEY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SOMATIC MUTATION; TRANSLATIONAL RESEARCH; VHL GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METASTASIS; MUTATION; PATHOLOGY; RENAL CELL CARCINOMA; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; EPIGENOMICS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84995678166     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw241     Document Type: Article

References (155)

1. http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-cancer-adultkey-statistics. 2016.
2. Maher ER. Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol 2013; 23: 10-17.
3. Chen F, Kishida T, Yao M et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995; 5: 66-75.
4. Crossey PA, Foster K, Richards FM et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 1994; 93: 53-58.
5. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704.
6. Vortmeyer AO, Huang SC, Pack SD et al. Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 2002; 21: 1167-1170.
7. Foster K, Prowse A, van den Berg A et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994; 3: 2169-2173.
8. Lubensky IA, Gnarra JR, Bertheau P et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996; 149: 2089-2094.
9. Mandriota SJ, Turner KJ, Davies DR et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1: 459-468.
10. Ohh M, Yauch RL, Lonergan KM et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1: 959-968.
11. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998; 95: 993-998.
12. Davidowitz EJ, Schoenfeld AR, Burk RD. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001; 21: 865-874.
13. Kondo K, Klco J, Nakamura E et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1: 237-246.
14. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995; 1: 822-826.
15. Chen F, Kishida T, Duh FM et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995; 55: 4804-4807.
16. Shenoy N, Shrivastava M, Sukrithan V et al. The regulation and interactions of the hypoxia inducible factor pathway in carcinogenesis and potential cancer therapeutic strategies. J Cancer Ther 2015; 6: 511.
17. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-214.
18. Hu CJ, Wang LY, Chodosh LA et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23: 9361-9374.
19. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 2015; 15: 55-64.
20. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264-6270.
21. Hara S, Hamada J, Kobayashi C et al. Expression and characterization of hypoxiainducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 2001; 287: 808-813.
22. Cockman ME, Masson N, Mole DR et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275: 25733-25741.
23. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19: 4298-4309.
24. Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
25. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
26. Baldewijns MM, van Vlodrop IJ, Vermeulen PB et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010; 221: 125-138.
27. Raval RR, Lau KW, Tran MG et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686.
28. Schodel J, Grampp S, Maher ER et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol 2015.
29. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1: E83.
30. Yan Q, Bartz S, Mao M et al. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol 2007; 27: 2092-2102.
31. Liu YV, Baek JH, Zhang H et al. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007; 25: 207-217.
32. Isaacs JS, Jung YJ, Mimnaugh EG et al. Hsp90 regulates a von Hippel Lindauindependent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002; 277: 29936-29944.
33. Holmquist-Mengelbier L, Fredlund E, Lofstedt T et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10: 413-423.
34. Myszczyszyn A, Czarnecka AM, Matak D et al. The role of hypoxia and cancer stem cells in renal cell carcinoma pathogenesis. Stem Cell Rev 2015; 11: 919-943.
35. Seidel S, Garvalov BK, Wirta V et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010; 133: 983-995.
36. Gassenmaier M, Chen D, Buchner A et al. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells 2013; 31: 1467-1476.
37. Guo M, Cai C, Zhao G et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma. PLoS One 2014; 9: e90518.
38. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-49.
39. Perroud B, Lee J, Valkova N et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006; 5: 64.
40. Zaravinos A, Pieri M, Mourmouras N et al. Altered metabolic pathways in clear cell renal cell carcinoma: a meta-analysis and validation study focused on the deregulated genes and their associated networks. Oncoscience 2014; 1: 117-131.
41. Xie H, Valera VA, Merino MJ et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009; 8: 626-635.
42. Piva F, Giulietti M, Santoni M et al. Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. Mol Diagn Ther 2016; 20: 111-117.
43. Pantuck AJ, An J, Liu H, Rettig MB. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res 2010; 70: 752-761.
44. Palayoor ST, Mitchell JB, Cerna D et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008; 123: 2430-2437.
45. Schwartz DL, Powis G, Thitai-Kumar A et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009; 8: 947-958.
46. Schwartz DL, Bankson JA, Lemos R, Jr et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010; 9: 2057-2067.
47. Brokers N, Le-Huu S, Vogel S et al. Increased chemoresistance induced by inhibition of HIF-prolyl-hydroxylase domain enzymes. Cancer Sci 2010; 101: 129-136.
48. Jiao M, Nan KJ. Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 2012; 40: 461-468.
49. Fischer C, Leithner K, Wohlkoenig C et al. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1alpha destabilization. Mol Cancer 2015; 14: 4.
50. Scala S, Akhmed N, Rao US et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol 1997; 51: 1024-1033.
51. Hodorova I, Rybarova S, Solar P et al. Multidrug resistance proteins in renal cell carcinoma. Folia Biol (Praha) 2008; 54: 187-192.
52. Vranic S, Hes O, Grossmann P, Gatalica Z. Low frequency of HIF-1alpha overexpression in germ cell tumors of the testis. Appl Immunohistochem Mol Morphol 2013; 21: 165-169.
53. Montani M, Heinimann K, von Teichman A et al. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cystdependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol 2010; 34: 806-815.
54. Frew IJ, Thoma CR, Georgiev S et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008; 27: 1747-1757.
55. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006; 66: 2576-2583.
56. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751-759.
57. Duns G, van den Berg E, van Duivenbode I et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 2010; 70: 4287-4291.
58. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-542.
59. Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014; 32: 1968-1976.
60. Albers J, Rajski M, Schonenberger D et al. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med 2013; 5: 949-964.
61. Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integr 2013; 4: 5.
62. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumors. Mol Cancer Res 2004; 2: 89-95.
63. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-1545.
64. Joshi S, Singh AR, Zulcic M, Durden DL. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1alpha and HIF2alpha stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res 2014; 12: 1520-1531.
65. Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 2008; 8: 19-26.
66. Kikuchi H, Pino MS, Zeng M et al. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and-2alpha in colon cancer. Cancer Res 2009; 69: 8499-8506.
67. Kang R, Hou W, Zhang Q et al. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis 2014; 5: e1480.
68. Lim JH, Lee ES, You HJ et al. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004; 23: 9427-9431.
69. Sun HL, Liu YN, Huang YT et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 2007; 26: 3941-3951.
70. Busca R, Berra E, Gaggioli C et al. Hypoxia-inducible factor 1(alpha) is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 2005; 170: 49-59.
71. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011; 2: e164.
72. Wu KJ, Yang MH. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection. Biosci Rep 2011; 31: 449-455.
73. Sun S, Ning X, Zhang Y et al. Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-tomesenchymal transition. Kidney Int 2009; 75: 1278-1287.
74. Han WQ, Zhu Q, Hu J et al. Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells. Biochim Biophys Acta 2013; 1833: 1454-1462.
75. Basu RK, Hubchak S, Hayashida T et al. Interdependence of HIF-1alpha and TGF-beta/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol 2011; 300: F898-905.
76. Phillips RJ, Mestas J, Gharaee-Kermani M et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280: 22473-22481.
77. Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 2006; 66: 11802-11807.
78. Gustafsson MV, Zheng X, Pereira T et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9: 617-628.
79. Diez H, Fischer A, Winkler A et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res 2007; 313: 1-9.
80. Zheng X, Linke S, Dias JM et al. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci USA 2008; 105: 3368-3373.
81. Chen S, Zhang M, Xing L et al. HIF-1alpha contributes to proliferation and invasiveness of neuroblastoma cells via SHH signaling. PLoS One 2015; 10: e0121115.
82. Shenoy N, Vallumsetla N, Zou Y et al. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol 2015; 8: 88.
83. Ye YW, Jiang ZM, Li WH et al. Down-regulation of TCF21 is associated with poor survival in clear cell renal cell carcinoma. Neoplasma 2012; 59: 599-605.
84. Costa VL, Henrique R, Danielsen SA et al. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 2011; 6: 1120-1130.
85. Haraldson K, Kashuba VI, Dmitriev AA et al. LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication. Biochimie 2012; 94: 1151-1157.
86. Gumz ML, Zou H, Kreinest PA et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007; 13: 4740-4749.
87. Kim WJ, Gersey Z, Daaka Y. Rap1GAP regulates renal cell carcinoma invasion. Cancer Lett 2012; 320: 65-71.
88. Kawai Y, Sakano S, Suehiro Y et al. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann Oncol 2010; 21: 1612-1617.
89. Lv D, Zhao W, Dong D et al. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. Eur J Cancer 2011; 47: 2068-2076.
90. Bennett KL, Campbell R, Ganapathi S et al. Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer 2011; 50: 654-661.
91. Paiva F, Duarte-Pereira S, Costa VL et al. Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms. DNA Cell Biol 2011; 30: 85-90.
92. Yoo KH, Park YK, Kim HS et al. Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Pathol Int 2010; 60: 661-666.
93. Hildebrandt MA, Gu J, Lin J et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29: 5724-5728.
94. Hirata H, Hinoda Y, Nakajima K et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 2011; 128: 1793-1803.
95. Kawakami K, Yamamura S, Hirata H et al. Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer 2011; 128: 541-550.
96. Cooper SJ, Zou H, Legrand SN et al. Loss of type III transforming growth factorbeta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene 2010; 29: 2905-2915.
97. Bachman KE, Herman JG, Corn PG et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798-802.
98. van Vlodrop IJ, Baldewijns MM, Smits KM et al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol 2010; 176: 575-584.
99. Kawakami K, Hirata H, Yamamura S et al. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 2009; 69: 8603-8610.
100. Seliger B, Handke D, Schabel E et al. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. J Transl Med 2009; 7: 90.
101. Majid S, Dar AA, Ahmad AE et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009; 30: 662-670.
102. Awakura Y, Nakamura E, Ito N et al. Methylation-associated silencing of TU3A in human cancers. Int J Oncol 2008; 33: 893-899.
103. Liang S, Xu Y, Shen G et al. Gene expression and methylation status of 14-3-3sigma in human renal carcinoma tissues. IUBMB Life 2008; 60: 534-540.
104. Sanz-Casla MT, Maestro ML, del Barco V et al. Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res 2003; 31: 159-162.
105. Kawamoto K, Hirata H, Kikuno N et al. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 2008; 123: 535-542.
106. Kvasha S, Gordiyuk V, Kondratov A et al. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 2008; 265: 250-257.
107. Reu FJ, Bae SI, Cherkassky L et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006; 24: 3771-3779.
108. Ahmad ST, Arjumand W, Seth A et al. Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol 2012; 33: 395-402.
109. Christoph F, Kempkensteffen C, Weikert S et al. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer 2006; 95: 1701-1707.
110. Zhang Q, Ying J, Zhang K et al. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett 2007; 249: 220-226.
111. To KK, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol 2006; 26: 8572-8585.
112. Kawakami T, Chano T, Minami K et al. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet 2006; 15: 821-830.
113. Okuda H, Toyota M, Ishida W et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 2006; 25: 1733-1742.
114. Yamada D, Kikuchi S, Williams YN et al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer 2006; 118: 916-923.
115. Morris MR, Gentle D, Abdulrahman M et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 2005; 65: 4598-4606.
116. Breault JE, Shiina H, Igawa M et al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res 2005; 11: 557-564.
117. Yano T, Ito F, Kobayashi K et al. Hypermethylation of the CpG island of connexin 32, a candiate tumor suppressor gene in renal cell carcinomas from hemodialysis patients. Cancer Lett 2004; 208: 137-142.
118. Nojima D, Nakajima K, Li LC et al. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog 2001; 32: 19-27.
119. Dunker K, Schlaf G, Bukur J et al. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens 2008; 72: 137-148.
120. Yoo KH, Park YK, Chang SG. DNA hypomethylation of interleukin 8 in clear cell renal cell carcinoma. Oncol Lett 2013; 5: 39-42.
121. Cho M, Grabmaier K, Kitahori Y et al. Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines. Mol Carcinog 2000; 27: 184-189.
122. Vanharanta S, Shu W, Brenet F et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med 2013; 19: 50-56.
123. Hu CY, Mohtat D, Yu Y et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res 2014; 20: 4349-4360.
124. Watson CJ, Collier P, Tea I et al. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblastlike phenotype. Hum Mol Genet 2014; 23: 2176-2188.
125. Ricketts CJ, Morris MR, Gentle D et al. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics 2013; 5: 16.
126. Hagiwara H, Sato H, Ohde Y et al. 5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene. Br J Pharmacol 2008; 153: 1373-1381.
127. Ramakrishnan S, Ellis L, Pili R. Histone modifications: implications in renal cell carcinoma. Epigenomics 2013; 5: 453-462.
128. Kanao K, Mikami S, Mizuno R et al. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008; 180: 1131-1136.
129. Mosashvilli D, Kahl P, Mertens C et al. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci 2010; 101: 2664-2669.
130. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-443.
131. Kong X, Lin Z, Liang D et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019-2028.
132. Sato A, Asano T, Isono M et al. Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth. Mol Clin Oncol 2014; 2: 1016-1022.
133. Manning J, Indrova M, Lubyova B et al. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 2008; 123: 218-227.
134. Frosig TM. Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma. Dan Med J 2015; 62: B5144.
135. Gang AO, Frosig TM, Brimnes MK et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J 2014; 4: e197.
136. Jung D, Hilmes C, Knuth A et al. Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 1999; 50: 242-249.
137. Wrangle J, Wang W, Koch A et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 2013; 4: 2067-2079.
138. Orskov AD, Treppendahl MB, Skovbo A et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015; 6: 9612-9626.
139. Biswas K, Richmond A, Rayman P et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 2006; 66: 6816-6825.
140. Thornton MV, Kudo D, Rayman P et al. Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 2004; 172: 3480-3490.
141. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
142. Pore N, Jiang Z, Shu HK et al. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 2006; 4: 471-479.
143. Dayan F, Bilton RL, Laferriere J et al. Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway. J Cell Physiol 2009; 218: 167-174.
144. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813.
145. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-731.
146. Motzer RJ, Porta C, Vogelzang NJ et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an openlabel, randomised phase 3 trial. Lancet Oncol 2014; 15: 286-296.
147. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14: 552-562.
148. Motzer RJ, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013; 31: 3791-3799.
149. Weiss A, Berndsen RH, Ding X et al. A streamlined search technology for identification of synergistic drug combinations. Sci Rep 2015; 5: 14508.
150. Jedeszko C, Paez-Ribes M, Di Desidero T et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med 2015; 7: 282ra250.
151. Iwata H, Sato H, Suzuki R et al. A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol 2011; 38: 1653-1661.
152. Onda K, Suzuki R, Tanaka S et al. Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines. Anticancer Res 2012; 32: 4439-4444.
153. Efferth T, Futscher BW, Osieka R. 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis 2001; 27: 637-648.
154. Pal SK, Haas NB. Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 2014; 19: 851-859.
155. Azzi S, Bruno S, Giron-Michel J et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 2011; 103: 1884-1898.